Advanced Imaging Analysis in Prostate MRI: Building a Radiomic Signature to Predict Tumor Aggressiveness.
magnetic resonance imaging
prostate cancer
prostate cancer aggressiveness
radiomics
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
19
02
2021
revised:
21
03
2021
accepted:
24
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Radiomics allows the extraction quantitative features from imaging, as imaging biomarkers of disease. The objective of this exploratory study is to implement a reproducible radiomic-pipeline for the extraction of a magnetic resonance imaging (MRI) signature for prostate cancer (PCa) aggressiveness. One hundred and two consecutive patients performing preoperative prostate multiparametric magnetic resonance imaging (mpMRI) and radical prostatectomy were enrolled. Multiparametric images, including T2-weighted (T2w), diffusion-weighted and dynamic contrast-enhanced images, were acquired at 1.5 T. Ninety-three imaging features (Ifs) were extracted from segmentation of index lesion. Ifs were ranked based on a stability rank and redundant Ifs were excluded. Using unsupervised hierarchical clustering, patients were grouped on the basis of similar radiomic patterns, whose association with Gleason Grade Group (GGG), extracapsular extension (ECE), and nodal involvement (pN) was tested. Signatures composed by IFs from T2w-images and Apparent Diffusion Coefficient (ADC) maps were tested for the prediction of GGG, ECE, and pN. T2w radiomic pattern was associated with pN, ECE, and GGG (
Identifiants
pubmed: 33810222
pii: diagnostics11040594
doi: 10.3390/diagnostics11040594
pmc: PMC8065545
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2007 Dec 27;357(26):2696-705
pubmed: 18160689
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Int Braz J Urol. 2009 Sep-Oct;35(5):559-64
pubmed: 19860934
MAGMA. 2017 Aug;30(4):359-373
pubmed: 28246950
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Breast Cancer Res Treat. 2017 Feb;161(3):605-616
pubmed: 28000015
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Urology. 2008 Jul;72(1):177-82
pubmed: 18279938
Eur Radiol. 2017 Jul;27(7):3050-3059
pubmed: 27975146
Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:5080-3
pubmed: 22255481
J Magn Reson Imaging. 2012 Jul;36(1):213-24
pubmed: 22337003
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2556-2567
pubmed: 32917666
Arch Pathol Lab Med. 2009 Oct;133(10):1568-76
pubmed: 19792046
NMR Biomed. 2014 Aug;27(8):887-96
pubmed: 24840393
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
J Magn Reson Imaging. 2016 Apr;43(4):990-7
pubmed: 26395278
AJR Am J Roentgenol. 2015 Mar;204(3):550-7
pubmed: 25714284
Am J Surg Pathol. 1997 May;21(5):566-76
pubmed: 9158682
Magn Reson Imaging. 2004 Jan;22(1):81-91
pubmed: 14972397
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2673-2699
pubmed: 31292700
Clin Radiol. 2004 Dec;59(12):1061-9
pubmed: 15556588
AJR Am J Roentgenol. 2011 Dec;197(6):1382-90
pubmed: 22109293
Eur Radiol. 2015 Oct;25(10):2840-50
pubmed: 25991476
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Appl Sci (Basel). 2021 Jan 2;11(2):
pubmed: 33680505
Curr Probl Diagn Radiol. 2021 Mar-Apr;50(2):175-185
pubmed: 31761413
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
Invest Radiol. 2011 Mar;46(3):160-8
pubmed: 21102348
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
PLoS One. 2019 Jul 8;14(7):e0217702
pubmed: 31283771
Front Oncol. 2018 Dec 18;8:630
pubmed: 30619764
Eur Radiol. 2013 Apr;23(4):1158-66
pubmed: 23114883